Market News & Trends
CEL-SCI Reports Record Monthly Patient Enrollment for Phase III Head & Neck Cancer Trial
CEL-SCI Corporation recently announced that during the month of April, it has enrolled 41 patients in its ongoing Phase III trial of its investigational immunotherapy…
Alder BioPharmaceuticals Licenses Clazakizumab Rights
Alder BioPharmaceuticals, Inc. and Vitaeris Inc. recently announced that Alder has licensed the exclusive worldwide rights to clazakizumab to Vitaeris. In exchange for the rights…
Meggle Announces New Head of Sales & Marketing
The Business Group Excipients & Technology of MEGGLE announced the appointment of Dr. Albrecht Kraemer, as its new Head of Sales & Marketing as…
Heart Failure Market to Soar to $11.8 Billion by 2025
The heart failure market is set to rise from around $3.2 billion in 2015 to $11.8 billion by 2025, representing a compound annual growth rate…
Oasmia Pharmaceutical Announces Positive Overall Survival Results From Phase III Study
Oasmia Pharmaceutical AB recently announced positive overall survival results for Paclical/Apealea in the Phase III study that included a total of 789 patients with epithelial…
Italy’s Pharmaceutical Industry Value Will Drop to $18.6 Billion by 2020
The pharmaceutical industry in Italy is set to decline from $21.3 billion in 2016 to $18.6 billion by 2020, at a negative compound annual growth…
Inovio Partners With National Cancer Institute & Mayo Clinic to Initiate Hepatitis C Immunotherapy Clinical Trial
Inovio Pharmaceuticals, Inc. recently announced its immunotherapy for hepatitis C (INO-8000) will be evaluated in a Phase I trial in chronically infected patients who are…
Celldex Therapeutics Initiates Phase I/II Study
Celldex Therapeutics, Inc. recently announced it has initiated an open-label Phase I/II safety and tolerability study of glembatumumab vedotin in patients with unresectable stage IIIB…
SERMO Collaborates With Wharton, Google & McKinsey & Company
SERMO recently announced its contribution to Pharma 3D: Rewriting the Script for Marketing in the Digital Age, an eBook released on April 27 by the…
VTU Technology & Boehringer Ingelheim Strengthen Their Global Microbial Technology Collaboration
VTU Technology, the Austrian protein expression expert announced today the expansion of their global technology collaboration with Boehringer Ingelheim RCV GmbH & Co. KG, a…
INTERPHEX & Industry Experts Select Nemera as Winner for Best New Product
International Pharmaceutical Expo (INTERPHEX), the premier event dedicated to pharmaceutical and biotechnology innovation, technology, and knowledge from development through commercialization and sponsored by the Parenteral…
First Gene Therapy Claims to be Successful Against Human Aging
Elizabeth Parrish, CEO of Bioviva USA Inc. has become the first human being to be successfully rejuvenated by gene therapy, after her own company’s experimental…
Bristol-Myers Squibb & Merck in Race to Dominate Head & Neck Cancer Market
Bristol-Myers Squibb & Merck in Race to Dominate Head & Neck Cancer Market Bristol-Myers Squibb (BMS) and Merck & Co. are set to continue…
Merrimack Unveils Its Latest Antibody-Directed Nanotherapeutic
Merrimack Pharmaceuticals, Inc. recently announced positive data from preclinical studies evaluating MM-310, an antibody-directed nanotherapeutic (ADN) that encapsulates a newly engineered form of the highly…
Baxter International Initiates Offer to Exchange Shares of Baxter for Shares of Baxalta
Baxter International Inc. and Baxalta Incorporated recently announced that Baxter has commenced an offer to exchange up to 12,800,000 shares of Baxalta common stock that…
Patheon Selected by Grünenthal to Develop Drugs Using INTAC(R) Abuse-Deterrent Formulations Technology
Patheon, the leading global provider of pharmaceutical development and manufacturing services today announced it has signed a strategic agreement with Grünenthal, an independent, family-owned, international…
New Structure Identified in Membrane of Disease-Causing Bacteria
Mycobacteria cause a number of dangerous, difficult-to-treat diseases including leprosy and tuberculosis, and progress has been slow in eradicating them. But new strategies for combating…
New Potential Lung Cancer Biomarkers Identified by The West Virginia University Cancer Institute
Protea Biosciences Group, Inc. recently announced the use of its proprietary bioanalytical technology to achieve the molecular profiling of live tumor cells while they are…
MorphoSys Licensing Partner GSK Starts Phase II Study
MorphoSys AG recently announced its licensing partner GlaxoSmithKline (GSK) has initiated a Phase II clinical study to investigate the effectiveness and safety of GSK3196165 (previously…
Multi-Blockbuster Drugs Will Drive Immuno-Oncology Market to $34 Billion by 2024
The total immuno-oncology market will be worth approximately $14 billion by 2019, rising to $34 billion by 2024, as the treatment of cancer patients undergoes…
